Tuesday, September 15, 2026
← Back to archivePolicy
Policy•KFF•Sep 15, 2026
FDA Regulation and the Dynamic Nature of AI
background ▾
- •The FDA has released a discussion paper on AI regulation and is soliciting stakeholder input on novel approaches to address the fundamental incompatibility between static 1976 device regulations and continuously learning AI systems.
- •Key regulatory uncertainty exists around post-market oversight and modification of AI/ML algorithms — the core challenge is that adaptive systems differ fundamentally from traditional fixed medical devices.
- •Watch for: FDA guidance documents on AI validation, real-world performance monitoring frameworks, and whether industry and payers converge on practical solutions before prescriptive legislation mandates inflexible requirements.
Policy•Endpoints News•Sep 15, 2026
FDA should require credentials for psychedelic providers, experts say
background ▾
- •Expert advocacy for FDA-mandated provider credentials signals growing concern about safety and standardization as psychedelic therapies approach market approval
- •Credentialing requirements could create barriers to market access and establish a professional services component that differentiates psychedelic drugs from traditional pharmaceuticals
- •FDA's regulatory response will determine whether psychedelic medicines follow a specialized clinical supervision model or integrate into standard psychiatric care delivery
Policy•STAT News•Sep 15, 2026
Opinion: 3 lessons from the tobacco settlement on how states should use money from Meta
background ▾
- •The 1998 tobacco settlement lacked spending restrictions, allowing states to divert funds to unrelated programs; tobacco prevention now receives only 3.4% of tobacco-related revenues despite the settlement's intent
Meta
→ Read original articlePolicy•Fierce Biotech•Sep 14, 2026
As ‘cultural weight’ of a psychedelic approval looms, FDA hearing focuses on access and safety
background ▾
- •FDA is preparing regulatory framework for psychedelic drug approval with critical decisions pending on who can administer treatments (psychiatrists vs. DSMs vs. nurses) and what training/credentialing is required
- •Clinical evidence presented indicates psychedelics are more effective when combined with therapy, yet companies are pursuing minimalist DSM models to reduce costs—creating fundamental conflict between efficacy data and commercial accessibility
- •Workforce readiness and standardized training requirements remain undefined; this regulatory gap could bottleneck patient access even after drug approvals
Compass PathwaysDefinium TherapeuticsSana Healing Collectivepsilocybin (Compass synthetic)LSD (Definium)ketamine
→ Read original articlePolicy•STAT News•Sep 14, 2026
Judge blocks Trump administration plans to limit visa length for grad students, postdocs
background ▾
- •Federal judge found the Trump administration's four-year visa cap for graduate students and postdocs likely violates the Administrative Procedure Act and lacks substantive national security rationale.
- •International researchers comprise a substantial portion of the U.S. biomedical workforce; blocking this policy protects institutional recruitment and workforce continuity for pharma, biotech, and academic research.
- •Monitor the full litigation outcome; if the injunction is lifted or the policy ultimately upheld, U.S. life sciences competitiveness and talent acquisition strategies could face significant disruption.
Market Access
Market Access•Fierce Biotech•Sep 15, 2026
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
background ▾
- •Novo abandoned a monthly GLP-1 development program despite a substantial upfront commitment, signaling either technical setbacks or strategic pivot regarding long-acting formulation timelines
- •Ascendis gains full control of TransCon Semaglutide and plans to independently develop it alongside other metabolic/cardiovascular programs, leveraging its approved TransCon platform track record (Yuviwel, Skytrofa, Yorvipath)
- •This represents the second major partnership dissolution under Novo's new leadership (following Inversago abandonment), suggesting systematic review of legacy deals and possible delays in achieving monthly dosing goals against competitors like Pfizer/Metsera
Novo NordiskAscendis PharmaPfizerTransCon SemaglutideWegovyYuviwel
→ Read original articleMarket Access•Fierce Biotech•Sep 14, 2026
J&J looking to offload orthopedics unit in $20B deal to Apollo: Bloomberg
background ▾
- •DePuy Synthes, a $9.3B revenue orthopedics business, is being divested to focus J&J on higher-growth pharmaceutical segments, consistent with competitor strategies (Novartis, Sanofi, Pfizer).
- •The $20B valuation reflects J&J's 15-year ownership (acquired Synthes for $21B in 2009) and positions Apollo as a major acquirer in medtech consolidation.
- •Monitor deal closure timeline (targeted within weeks), alternative bidder emergence, and potential IPO pivot; watch impact on DePuy's competitive positioning against Stryker and Zimmer Biomet under PE ownership.
Johnson & JohnsonApollo Equity ManagementStryker
→ Read original articleMarket Access•Endpoints News•Sep 14, 2026
GSK to wind down German vaccine factory due to lack of demand
background ▾
- •Egg-based flu vaccine demand is declining as payers and physicians shift toward cell-based and recombinant alternatives with better clinical profiles
- •This represents a significant operational restructuring with 650 job losses, signaling GSK's pivot away from legacy vaccine manufacturing platforms
- •Watch for clarity on GSK's timeline for closure, capacity reallocation to other production sites, and the company's competitive positioning in next-generation flu vaccines
GSKEgg-based influenza vaccine
→ Read original articleMarket Access•Endpoints News•Sep 14, 2026
Novo Nordisk shortens its name in brand and culture reboot
background ▾
- •Novo Nordisk is rebranding with a shortened name and new culture strategy following operational setbacks in 2024
Novo Nordisk
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 14, 2026
Lilly cans early experimental obesity drug after ‘high bar’ not met
background ▾
- •Lilly terminated Phase 1 of LY4064912 after failing internal 'high bar' for continued development, highlighting the company's selective gatekeeping in an increasingly crowded obesity market
- •Lilly has shifted to opacity in early-stage pipeline disclosure, removing projects from public websites and earnings updates, limiting visibility into portfolio breadth
- •The company's focus remains on late-stage assets (retatrutide in Phase 3 targeting Q1 2027 FDA submission) and approved blockbusters, suggesting confidence in current pipeline depth
Eli LillyKura OncologyLY4064912ZepboundFoundayoo
→ Read original articleClinical Trials•Fierce Biotech•Sep 14, 2026
The signal that changes everything: understanding MRD in oncology drug development
background ▾
- •MRD-guided trial designs (TOMR) enable enrollment of higher-risk ctDNA-positive patients with dramatic efficiency gains: IMvigor011 showed 55% median OS improvement, 2x median DFS improvement, and required 70% fewer patients with 62% faster time to interim analysis
- •Early ctDNA clearance within weeks of treatment initiation predicts long-term outcomes and enables earlier regulatory milestones; Allogene's cemacabtagene ansegedleucel achieved FDA RMAT and Fast Track designations based on Day 45 MRD data
- •Assay analytical sensitivity is critical—nearly 50% of MRD-positive cases detected at ≤100 ppm would be missed by less sensitive assays, creating risk of false-negative results that could impact treatment decisions
Allogene TherapeuticsNateraRoche/Genentechatezolizumabcemacabtagene ansegedleucel
→ Read original articleClinical Trials•Fierce Biotech•Sep 15, 2026
Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide
background ▾
- •NX210c failed to meet its primary endpoint of reducing plasma neurofilament light chain, a validated ALS biomarker, though secondary motor function improvements and BBB restoration markers were observed
- •The company's strategy to pivot focus to secondary endpoints and pursue multi-indication development (Alzheimer's, Parkinson's, MS) may face skepticism from regulators and investors without a clear path to ALS efficacy demonstration
- •Watch for design and endpoint selection in the next phase 2b/3 trial, regulatory feedback on BBB restoration as a surrogate for clinical benefit, and competitive positioning against emerging ALS therapies like COYA 302
Axoltis PharmaBiogenMitsubishi TanabeNX210cTofersenRadicava
→ Read original articleClinical Trials•STAT News•Sep 15, 2026
Exercise — and echocardiograms — in space protected astronauts’ hearts in study
background ▾
- •Exercise countermeasures successfully prevented prolonged cardiovascular dysfunction in astronauts during six-month spaceflight, with cardiac changes reversible upon return to Earth
- •First study to comprehensively describe full cardiovascular adaptation to prolonged spaceflight using echocardiography imaging rather than indirect markers like blood pressure and heart rate
- •Critical gap: unknown outcomes for astronauts unable to exercise due to injury or other medical complications during extended missions, representing a risk factor for future Mars missions
Clinical Trials•Endpoints News•Sep 14, 2026
Electra aims for nearly $300M IPO; Enhertu's Phase 3 lung cancer success
background ▾
- •Enhertu Phase 3 lung cancer success expands the drug's clinical profile and potential market opportunity in a large disease area
- •Electra's $297M IPO signals continued investor appetite for Sanofi-incubated biotech programs despite broader market conditions
- •Regulatory approval timelines and competing lung cancer therapies will determine commercial impact of Enhertu's new indication
Daiichi SankyoSanofiElectra TherapeuticsEnhertu
→ Read original article